Tackling metabolic disorders with non-coding RNAs
Resalis Therapeutics is dedicated to developing RNA-based therapies that tackle the root causes of complex metabolic disorders.
With strong preclinical data supporting its development, RES-010 is now entering clinical trials, positioning Resalis Therapeutics as a key company in the evolving landscape of obesity treatment.
We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate, RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.
Members of our management team will be at:
1st Annual BioPharma Obesity Innovation Forum 2025
January 11, San Francisco
JPM Healthcare Conference 2025
January 13-16, San Francisco